JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

220.59 1.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

218.78

Máximo

222.59

Métricas clave
By Trading Economics
Ingresos	-22M -61M
Ventas	56M 214M
Margen de beneficio	-28.549
Empleados	1,017
EBITDA	-56M -53M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+24.73% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	1.8B 14B
Apertura anterior	219.09
Cierre anterior	220.59

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

275 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 feb 2026, 09:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Adquisiciones, fusiones, absorciones

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Charlas de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Ganancias

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Charlas de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Ganancias

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 feb 2026, 20:27 UTC

Ganancias

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 feb 2026, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 feb 2026, 19:48 UTC

Ganancias

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 feb 2026, 19:17 UTC

Charlas de Mercado

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 feb 2026, 18:50 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 18:47 UTC

Charlas de Mercado

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 feb 2026, 18:34 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 feb 2026, 17:58 UTC

Ganancias

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

24.73% repunte

Estimación a 12 meses

Media 277.08 USD 24.73%

Máximo 342 USD

Mínimo 240 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

275 / 352 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.